






 WILEY



Concepts in Genetic Medicine



EDITED BY

BORO DROPULIC • BARRIE CARTER

CONTENTS

CONTRIBUTORS	ix
PREFACE	xiii
INTRODUCTION	
1 The Evolution of Human Gene Therapy: A Journey from Excessive Hype to Excessive Diffidence to Reality	1
<i>Theodore Friedmann</i>	
VECTOR SYSTEMS	
2 Murine Leukemia Virus–Based Retroviral Vectors	7
<i>Kenneth Cornetta</i>	
3 Lentivirus Vectors	19
<i>Gwendolyn K. Binder and Boro Dropulic</i>	
4 Adenoviral Vectors: History and Perspective	39
<i>Douglas J. Jolly, Estuardo Aguilar–Cordova, and Laura K. Aguilar</i>	
5 Adeno-Associated Virus Vectors	61
<i>Barrie J. Carter</i>	
6 SV40 Virus–Derived Vectors	69
<i>David S. Strayer</i>	
7 Herpes Simplex Virus Vectors	85
<i>Anna-Maria Anesti and Robert S. Coffin</i>	
8 Nonviral Gene Delivery Systems	103
<i>Takeshi Suda and Dexi Liu</i>	

APPLICATIONS

- 9 Therapeutic Gene Transfer to Skeletal Muscle** 123
Paul Gregorevic and Jeffrey S. Chamberlain
- 10 Gene Therapy for Cardiovascular Disease** 129
Christina A. Pacak, Kerry O. Cresawn, and Barry J. Byrne
- 11 Intraarticular Vector Delivery for Inflammatory Joint Disease** 137
Haim Burstein
- 12 The Respiratory System as a Platform for Gene Delivery** 145
Barrie J. Carter
- 13 The Brain as a Target for Gene Therapy** 153
Pedro R. Lowenstein and Maria G. Castro
- 14 Immune Responses to Viral Vectors Injected Systemically or into the CNS** 167
Pedro R. Lowenstein and Maria G. Castro
- 15 Cancer Vaccines** 181
Rimas J. Qrentas
- 16 Genetically Modified T Cells for Human Gene Therapy** 193
James L. Riley and Carl H. June
- 17 Lentiviral Vector Delivery of RNAi for the Treatment of HIV-1 Infection** 207
Kevin V. Morris and John J. Rossi
- 18 Vector Targeting** 223
Qiana L. Matthews and David T. Curiel

THE MANUFACTURE OF GENE THERAPY PRODUCTS

- 19 The Manufacture of Genetic Viral Vector Products** 229
Douglas J. Jolly and Estuardo Aguilar-Cordova
- 20 The Manufacture of Adeno-Associated Viral Vectors** 245
Richard Peluso

21	Lentivirus Vector Manufacturing	253
	<i>Gwendolyn K. Binder and Boro Dropulic</i>	

SAFETY AND REGULATORY CONSIDERATIONS

22	Assays for the Release of Viral Vector Gene Therapy Products for Human Clinical Trials	269
	<i>Flavia Borellini</i>	

23	Safety of Retroviral Vectors: Regulatory and Technical Considerations	277
	<i>Kenneth Cornetta and Carolyn A. Wilson</i>	

24	Assays for the Quality Control of Lentiviral Vectors	289
	<i>James E. Miskin, Susan M. Kingsman, and Kyriacos A. Mitrophanous</i>	

25	Assays for Nonviral Vectors	299
	<i>Ralph W. Paul</i>	

26	Assays for the Release of Cellular Gene Therapy Products	307
	<i>Philip J. Cross and Bruce L. Levine</i>	

27	Toxicology for Gene Therapy Products: Concepts and Challenges	319
	<i>Russette M. Lyons</i>	

28	Regulatory Aspects of Gene Therapy Medicinal Products in the European Union	329
	<i>Matthias Schweizer, Christian J. Buchholz, and Klaus Cichutek</i>	

FINANCE AND REIMBURSEMENT

29	Venture Capital and Biotechnology Startups	341
	<i>Douglas D. Lind</i>	

30	The Role of Investment Banking in the Growth of Biotechnology Companies	351
	<i>Douglas J. Swirsky</i>	

31	Managing Reimbursement for Gene Therapy Products	355
	<i>Martin Gold</i>	